As-needed albuterol-budesonide (Airsupra) more effectively improved lung function in moderate-to-severe asthma than as-needed albuterol only, according to research presented at the CHEST annual meeting hosted by the American College of Chest Physicians.
In this exclusive MedPage Today video, study author Reynold Panettieri Jr., MD, vice chancellor for Translational Medicine and science director of Rutgers Institute for Translational Medicine in New Brunswick, New Jersey, discusses the post hoc assessment reporting on lung function data from the phase III MANDALA study.
Following is a transcript of his remarks:
Thank you so much for the opportunity to describe our poster that was presented at the exciting CHEST meeting of 2023.
The MANDALA study was a study where patients were randomized to either albuterol/ICS [inhaled corticosteroid], that is albuterol-budesonide, or albuterol rescue, on top of standard of care maintenance therapy. Remarkably, the adherence to the standard of care ICS level is very, very good.
And what we found is in those patients, those patients randomized to albuterol-budesonide versus albuterol alone, there were fewer exacerbations over the period of time of the study, as well as an improvement in their lung function.
Now, one could ask, well, why would someone have an improvement in their lung function if they’re using a rescue? So this is one of the first times ever someone has shown that rescue therapy can actually improve the FEV1 [forced expiratory volume in 1 second] over weeks of the trial on top of standard of care and decrease the exacerbation rate.
So, very exciting new data as Airsupra [albuterol-budesonide] becomes available. We’re thrilled that the concept of using albuterol-budesonide as rescue can enhance the quality of care of patients with uncontrolled asthma.